Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 14/20 | 0.75 |
| ▸ | SRD5A2 | P31213 | 7/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.75 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.75 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.75 |
| ▸ | HSD3B1 | P14060 | 1/20 | 0.75 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | THPO | P40225 | 1/20 | 0.75 |
| ▸ | BLM | P54132 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8777107 | 0.91 | SRD5A1 (0.72) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8777104 | 0.91 | SRD5A1 (0.72) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8777125 | 0.91 | SRD5A1 (0.72) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8777091 | 0.91 | SRD5A1 (0.70) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8777093 | 0.91 | SRD5A1 (0.70) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8777172 | 0.91 | SRD5A1 (0.70) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL11954113 | 0.89 | SRD5A1 (0.80) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8793048 | 0.89 | SRD5A1 (0.73) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8793051 | 0.89 | SRD5A1 (0.73) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 | |
| SCHEMBL8777111 | 0.88 | SRD5A1 (0.70) | SRD5A1SRD5A2LMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5595985-A | Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia | ENDORECHERCHE INC. (CA) | 1997-01-21 | — | — | US | claimed |
| US-20120029260-A1 | Screening and Treatment Method | BIOVIE INC. | 2012-02-02 | — | — | US | disclosed |
| US-20110085984-A1 | Drug Product and Process for Making | BIOVIE INC. | 2011-04-14 | — | — | US | disclosed |
| US-20070077203-A1 | Surrogate markers | BIOVIE INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070053832-A1 | Drug product and process for making | BIOVIE INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070077203-A1 | Surrogate markers | TSG101, RAD50, DNASE1L3 | SRD5A1 3667/4885SRD5A2 3610/4885LMNA 230/4885 |
| US-20110085984-A1 | Drug Product and Process for Making | CYP2D6, CYP3A5, CYP2B6 | SRD5A1 716/4885SRD5A2 603/4885LMNA 2153/4885 |
| US-20070053832-A1 | Drug product and process for making | CYP2D6, CYP3A5, CYP2B6 | SRD5A1 716/4885SRD5A2 603/4885LMNA 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.